Home HealthCare Cumberland Pharmaceuticals Declares Kenneth J. Krogulski To Join Its Board Of Directors;

Cumberland Pharmaceuticals Declares Kenneth J. Krogulski To Join Its Board Of Directors;

1
0
SHARE

News: Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) belongs to Healthcare sector and Drug Manufacturers industry. Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) is glad to pronounce the expansion of Kenneth J. Krogulski, CFA to its Board of Directors. He is the President and Chief Executive Officer of Berkshire Asset Administration LLC. He is additionally the Chief Investment Officer of Berkshire, a 30-year-old free SEC enrolled speculation consultative firm with over $1.5 billion under organization.

Mr. Krogulski has more than 37 years’ involvement in security examination and portfolio organization. He started his profession in back at First Eastern Bank (now PNC Financial) as a venture investigation and portfolio supervisor. He then served as senior portfolio supervisor in First Easter’s Trust division. Mr. Krogulski then joined Berkshire and later drove an organization purchase out getting the organization from Legg Mason. Under his initiative, Berkshire’s advantages under supervision have developed from $600 million in 2006 and are presently over $1.5 billion.

He earned his B.S. in fund from Indiana University of Pennsylvania and his M.B.A from Wilkes University. He holds the Chartered Financial Analysts assignment.

“Ken adds another point of view to our Board, given his part and experience as a shareholder and portfolio director,” said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. “We anticipate working with him as we try to hoist Cumberland’s open organization profile.”

“I am awed with Cumberland’s demonstrated organization group, solid essentials and developing arrangement of claim to fame marked pharmaceuticals,” said Ken Krogulski. “I anticipate working with the group at Cumberland to propel the Company’s main goal of improving patient care, while likewise constructing noteworthyshareholder esteem.”

Mr. Krogulski’s arrangement to Cumberland’s Board as a free chief will be powerful January 18, 2017. Cumberland’s Board of Directors likewise incorporates Joey Jacobs, Chairman and CEO of Acadia Healthcare, Dr. Gordon Bernard, Associate Vice-Chancellor for Research atVanderbilt University Medical Center, Jamie Jones, previous Managing Partner of KPMG LLP’s Middle Tennessee operations, Thomas Lawrence, Chairman of Aetos Technologies, Jon Griggs, Former Vice President at Warner-Lambert Company, and Caroline Young, previous President of the Nashville Healthcare Council, who additionally all serve as autonomous chiefs.

Summary: Cumberland Pharmaceuticals Inc. is a forte pharmaceutical organization concentrated on securing, advancement, and commercialization of astounding items that enhance the nature of look after patients. The Company has a differing item portfolio with a concentration in the territories of healing facility intense care and gastroenterology.

Cumberland’s promoted items incorporate Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen harming, Caldolor® (ibuprofen) Injection, the main injectable treatment for agony and fever affirmed in the United States, Kristalose® (lactulose) for Oral Solution, a medicine purgative, Vaprisol® (conivaptan) Injection, for the treatment of hyponatremia, Omeclamox-Pak® for the treatment of H. pylori and duodenal ulcer malady, and Ethyol® (amifostine) for Injection, for the avoidance of treatment-related antagonistic responses in oncology patients. Cumberland is additionally committed to creating inventive items that address neglected therapeutic needs.